Interview with Rubens Lima, General Manager, Ipsen Brazil
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
Address: Av. Luis Carlos Berrini, 1297 cj 61 – Cidade Monções São Paulo – SP – CEP: 04571-010 Brasil,Brazil
Tel: -5693
Web: http://www.ipsen.com/en/ipsen-worldwide
Ipsen is a group that operates in the global biotechnology and pharmaceutical innovation in medical specialties with more than 20 in the world market. The Ipsen Group has a worldwide staff of about 4,000 employees. Its development strategy is based on a combination of special medicines in several therapeutic areas (oncology, endocrinology, neurology and hematology) and primary care products. The company has four R & D centers (Paris, Boston, Barcelona and London) and has a group of highly qualified researchers. More than 900 people in R & D are dedicated to the discovery of innovative medicines. This strategy is also supported by an active policy of partnerships of the Ipsen Group.
In 2010, total revenue was € 1.1 billion (USD $ 1.6 billion). Ipsen invested approximately € 220 million (USD $ 315 million, or 20% of consolidated sales) on research and development (a larger percentage of the global pharmaceutical industry). Ipsen has an extensive and sophisticated R & D program, which includes about 20 lines of research, from preclinical to Phase III.
The company’s clinical trials in Brazil are conducted in partnership with major research centers like the University of São Paulo (USP), Federal University of Rio de Janeiro (UFRJ), Universidade de Brasília (UnB) and Catholic University of Porto Alegre.
Dysport ® (Botulinum toxin type A, 500U, for the treatment of dystonias, spasticity and cosmetic uses), Somatuline ® Autogel ® (lanreotide for the treatment of acromegaly and neuroendocrine tumors), Apokyn ® (apomorphine for the treatment of the syndrome. advanced Parkinson’s), Nutropin ® (growth hormone) and INCRELEX ® (IGF-1 for the treatment of growth deficits).
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
Rodrigo Araujo of global organizational consulting firm Korn Ferry outlines what he sees as the leadership profile of the future – agile, digital, self-aware, and able to transform both themselves…
When combining the sheer size of Brazil – the fifth largest country in the world – with its tropical climate, its largely perfectible infrastructure, and the soaring importance of temperature…
“Brazil undoubtedly holds great development opportunities for the global pharmaceutical and healthcare industries,” boldly states Minister of Health Ricardo Barros, “and we hope to gain the trust of an increasing…
Maria del Pilar Muñoz, vice-president in charge of M&A and Sustainability at Eurofarma, one of the largest and most innovative pharmaceutical companies in Brazil with operations in 20 countries across…
Luciano Marques, president of Alcon Brazil, provides insights into recent investments and innovative initiatives aimed at strengthening Alcon’s relationships with its partners and customers in Brazil, and also documents the…
Armando Correa Lopes Jr, managing director of Siemens Healthineers Brazil, provides insights into the main trends and challenges at the core of Brazil’s healthcare discussion and documents the contribution of…
Tatiane Galindo, executive director of Ortosintese, Brazil’s and Latin America’s leading implant company, provides insights into Ortosintese’s historical commitment to the highest quality standards and her ambitions to further bolstering…
Fernando Itzaina, president and CEO of FQM Group, originally Farmoquímica, provides inspiring insights into the threefold development vision favored by this rapidly growing pharmaceutical company, his commitment to continue exploring…
Prof. Dr. Luiz Calistro Balestrassi, founder and president of NEUROTEC® – Biomedical Research & Development Company from Itajubá-MG, Brazil, and his daughter Esperança Balestrassi, Neurotec´s executive director, discuss the past,…
Paulo Vitor de Andrade, founder and director of Grupo Polar, elaborates on his journey to build the Brazilian company of reference in cold chain solutions and the company’s relentless efforts…
Poul Sorensen, director of Geistlich Pharma in Brazil, details the importance of educational activities for Geistlich’s business, the affiliate’s desire to bring new segments of Geistlich’s portfolio to Brazil and…
Jun Eguti, general manager of Grünenthal Brazil, highlights the global transformation Grünenthal has undergone in the past two years, the huge potential the Brazilian affiliate has to become one of…
See our Cookie Privacy Policy Here